Denis Chem Lab reported a net profit of ₹204.52 lakh for the quarter ended June 30, 2026, compared to ₹247.50 lakh in the same period of the previous year. The Ahmedabad-based manufacturer of parenteral products saw its revenue from operations rise 1.7% year-on-year to ₹4,399.67 lakh, up from ₹4,327.59 lakh in Q1FY26.

The company’s Board of Directors approved the unaudited financial results at a meeting held on August 13, 2026. The statutory auditors, Shah & Shah Associates, issued an unmodified opinion on the interim financial information.

Financial Performance

Revenue growth was modest but consistent with the prior year’s trajectory. While cost of materials consumed increased by 5% to ₹2,383.17 lakh from ₹2,270.62 lakh, the company managed to contain other significant expense heads. Employee benefits expense rose 17.2% to ₹419.35 lakh, reflecting ongoing workforce costs, while finance costs declined sharply by 41.8% to ₹10.79 lakh from ₹18.55 lakh.

Earnings per share (EPS) stood at ₹1.47 for the quarter, down from ₹1.78 in Q1FY26. The company recorded no exceptional items or discontinued operations during the period.

What the Numbers Show

A key divergence in the results is the behavior of other income versus operating profitability. Other income surged nearly 50% year-on-year to ₹45.00 lakh from ₹30.02 lakh, contributing significantly to total income. However, this gain was offset by a contraction in net profit, indicating that core operating margins faced pressure despite the rise in non-operating gains. The increase in total expenses (3.8%) outpaced revenue growth (1.7%), suggesting input cost inflation or volume-mix shifts impacted bottom-line efficiency more than top-line expansion.

Regulatory and Operational Notes

The company operates solely in one segment: manufacturing and sales of transfusion solutions in bottles. It has no subsidiaries or associates. The filing notes that figures for the previous quarter ended March 31, 2026, represent balancing figures between audited full-year data and unaudited nine-month figures.

Denis Chem Lab continues to monitor the implementation of the four Labour Codes notified by the Government of India in November 2025. In the previous quarter, the company recorded impacts on gratuity and privilege leave due to changes in wage definitions, as per guidance from the Institute of Chartered Accountants of India. No outstanding defaults on loans or debt securities were reported.

Denis Chem Lab Limited has scheduled its 45th Annual General Meeting (AGM) for September 25, 2026, and fixed September 18, 2026, as the record date for determining dividend entitlements for FY26. The company emphasized that physical shareholders must update their Know Your Customer (KYC) details with the Registrar and Transfer Agent (RTA) to receive dividends electronically, as mandated by SEBI regulations. Failure to update PAN, nomination, contact details, bank account information, or signatures will restrict dividend payments to electronic mode only.

The Board of Directors, in a meeting held on July 29, 2026, approved the convening of the AGM via Video Conference (VC) or Other Audio Visual Means (OAVM), in compliance with Ministry of Corporate Affairs (MCA) General Circular No. 03/2025 dated September 22, 2025, and General Circular No. 20/2020 dated May 5, 2020. The meeting will transact business including the reappointment of Dr. Himanshu C. Patel as Managing Director for a three-year term effective August 1, 2026, and the appointment of M/s. Kashyap R. Mehta & Partners as Secretarial Auditor for five financial years from FY27 to FY31.

Shareholder Compliance and Voting

Shareholders holding shares as of the cutoff date for dispatch will receive the AGM notice and Annual Report for FY26 via electronic mode. The notice will also be available on the company’s website at investors.denis.com , BSE Limited’s website, and the Central Depository Services (India) Limited (CDSL) e-voting portal at evotingindia.com .

Remote e-voting will commence at 9:00 a.m. on September 22, 2026, and conclude at 5:00 p.m. on September 24, 2026, in accordance with Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. E-voting during the AGM itself will remain active for 15 minutes after the meeting’s conclusion. Members attending via VC/OAVM will be counted toward the quorum under Section 103 of the Companies Act, 2013.

Dividend Payment Procedures

The final dividend, if declared, will be paid within 30 days of the AGM to members whose names appear on the register as of September 18, 2026. For demat holders, eligibility is determined by data furnished by National Securities Depository Limited (NSDL) and CDSL. Physical shareholders are required to submit folio numbers, scanned share certificates, self-attested PAN and Aadhaar cards, and bank details with a cancelled cheque to MUFG Intime India Private Limited at investor.helpdesk@in.mpmis.mufg.com . Demat holders must coordinate with their Depository Participants to register bank details and email addresses.

Governance Updates

Dr. Himanshu C. Patel, who holds B.E., M.S., and Ph.D. qualifications, continues his leadership role with over four decades of experience in the medical and pharmaceutical sectors. He currently holds 2,048,137 equity shares in the company. The Nomination and Remuneration Committee recommended his reappointment following the expiration of his previous term on July 31, 2026. M/s. Kashyap R. Mehta & Partners, led by Yash K. Mehta, will conduct the secretarial audit to ensure compliance with SEBI Listing Regulations and the Companies Act, 2013.